Key Highlights

  • The shares fell with no new company announcement identified on the day.
  • Cash fell by more than £3 million over the financial year, including investigation costs.
  • Trading was suspended from 1 April to 8 June 2026 while revenue issues were investigated.
  • Revenue growth has relied heavily on an acquired contract manufacturing business.
  • Full-year results are expected in December.

SkinBioTherapeutics plc (LSE:SBTX) is an AIM-quoted life science company focused on skin health. It develops products based on its SkinBiotix microbiome platform, sells the AxisBiotix range of food supplements and owns the Dermatonics foot-care brand. It has also expanded into contract manufacturing through an acquisition.

Why Did SkinBioTherapeutics (LSE:SBTX) Fall by 6.17% on 22 October 2026?

SkinBioTherapeutics fell by 6.17% on 22 October. No new company announcement was identified on the day; the most recent update was a change of registered office on 15 October.

The shares remain under pressure following a turbulent year. A trading statement in late September showed revenue growth, but much of it came from the acquired contract manufacturing business, and cash fell by more than £3 million. With limited liquidity, the shares can move sharply on modest trading.

The Business Model of SkinBioTherapeutics

The company generates revenue from consumer health products, including AxisBiotix supplements aimed at skin conditions, Dermatonics foot-care products and contract manufacturing services.

Its long-term strategy is to commercialise microbiome-based skin health products, supported by clinical studies and partnerships.

Growth has relied heavily on the acquired manufacturing business, while sales of its own branded products remain modest.

Key Reasons Behind Decline

Falling cash resources

Cash fell by more than £3 million in the year, including investigation costs, leaving limited headroom if losses continue.

Legacy of the revenue investigation

The company disclosed that an independent investigation found documentation supporting certain previously reported revenue had been fabricated by its former chief executive, with no evidence of others’ involvement. This led to a trading suspension and restatement.

Dependence on contract manufacturing

Revenue growth has come mainly from the acquired business rather than the company’s own products.

Index removal

The shares were removed from the FTSE AIM All-Share after the prolonged suspension, which can reduce demand from index-tracking investors.

Risks Investors Need to Consider

Funding risk is the most immediate concern. If losses persist, the company may need to raise additional capital.

Reputational risk from the revenue investigation may affect relationships with partners and investors.

Commercial risk applies to growing branded product sales in competitive consumer health markets.

Figures in the September trading statement are unaudited and could change before full-year results are published.

What Is the Dividend Outlook?

SkinBioTherapeutics does not pay a dividend. The company is focused on stabilising its finances and growing revenue.

Distributions would require sustained profitability and a healthier cash position, which are not expected in the near term.

What Does the ESG Investment Case Look Like?

Environmental considerations include sustainable sourcing and manufacturing practices.

Social factors include product safety and the responsible marketing of health supplements.

Governance is the most important ESG issue. Following the revenue investigation, the company has appointed an interim chief financial officer and strengthened non-executive leadership. Investors will watch for effective controls and transparent reporting.

What Are the Bull and Bear Cases for LSE:SBTX?

Bull Case:

  • Revenue is growing, supported by contract manufacturing.
  • Board and finance changes may improve governance.
  • AxisBiotix and Dermatonics provide established product lines.
  • The company intends to pursue recovery of investigation costs.

Bear Case:

  • Falling cash may require dilutive funding.
  • Reputational damage could weigh on partnerships.
  • Branded product sales remain modest.
  • Low liquidity can amplify declines.

The positive case rests on stabilising finances and growing product sales; the negative case centres on funding risk and the legacy of the revenue investigation.

Technical Levels to Watch

  • Support Zone: Recent lows established in early October are the key reference level.
  • Resistance Levels: Levels seen after trading resumed in June may act as resistance.
  • Volume Trends: Moves on light volume should be treated with caution.
  • Momentum Indicators: Stabilisation in momentum would suggest the market is waiting for full-year results.

Outlook

SkinBioTherapeutics is working to rebuild after a difficult year, but falling cash and reliance on contract manufacturing keep investors cautious. The latest decline reflects that fragile sentiment rather than new information.

Audited full-year results, expected in December, will be important for confirming revenue and cash figures. Evidence of improving branded sales and a clear funding plan would be needed to support a recovery.